Taken together, our data suggest that PD-1 is induced on T-bet+ ILCs by tumor-derived lactate, which then selectively inhibits the proliferation of the T-bet+ ILC within the TME by modulating metabolic pathways. The gene discussed is PDCD1; the disease is neoplasm.